YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is plea…
Innovation Pharmaceuticals Inc WAKEFIELD, MA, June 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the United States Paten…
WAKEFIELD, MA, June 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the United States Patent and Trade Office (USPTO), on…
Innovation Pharmaceuticals Inc WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Te…
WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleas…
Innovation Pharmaceuticals Inc WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced publication of Brilac…
WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced publication of Brilacidin antifungal research in Nat…
WAKEFIELD, MA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that based on positive findings new testing of Brilac…
Innovation Pharmaceuticals Inc WAKEFIELD, MA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that based on positive…
Innovation Pharmaceuticals Inc WAKEFIELD, MA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Te…
WAKEFIELD, MA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleas…
Multiyear Development and Support Agreement Lays the Foundation for the Realization of an Advanced Software Suite to Enable Revolutionary Treatments of Epilepsy and Brain Tumors WAKEFIELD, MA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- via NewMedia…
Innovation Pharmaceuticals Inc Multiyear Development and Support Agreement Lays the Foundation for the Realization of an Advanced Software Suite to Enable Revolutionary Treatments of Epilepsy and Brain Tumors WAKEFIELD, MA, Jan. 09, 2023 (…
Innovation Pharmaceuticals Inc Additionally, Brilacidin to be Screened by NIH/NIAID to Further Characterize Its Broad-Spectrum Antifungal Activity WAKEFIELD, MA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceutica…
Additionally, Brilacidin to be Screened by NIH/NIAID to Further Characterize Its Broad-Spectrum Antifungal Activity WAKEFIELD, MA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”)…
Innovation Pharmaceuticals Inc Regulatory clearance lays key technological and regulatory foundation for BT BeaMedical’s vision of revolutionizing treatment options in neurosurgery, oncology, and a wide spectrum of other clinical specialti…
Regulatory clearance lays key technological and regulatory foundation for BT BeaMedical’s vision of revolutionizing treatment options in neurosurgery, oncology, and a wide spectrum of other clinical specialties. WAKEFIELD, MA, Nov. 28, 202…
BARDA prioritizing the development of host-targeting and pathogen-agnostic therapeutics for treatment of hospitalized COVID-19 and other serious diseases of the lung Wakefield, MA - (NewMediaWire) - November 15, 2022 - Innovation Pharmaceu…
Innovation Pharmaceuticals Inc Innovation Pharmaceuticals believes U.K. launch of MRgLITT for refractory focal epilepsy substantiates its investment in advanced laser technology of BT BeaMedical WAKEFIELD, MA, Oct. 26, 2022 (GLOBE NEWSWIRE…
Innovation Pharmaceuticals believes U.K. launch of MRgLITT for refractory focal epilepsy substantiates its investment in advanced laser technology of BT BeaMedical WAKEFIELD, MA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innova…
Innovation Pharmaceuticals Inc In pre-clinical studies, Brilacidin shown to synergize with marketed antifungals against pathogenic species of aspergillosis, candidiasis, cryptococcosis and mucormycosis, and further exhibited potent stand-a…
In pre-clinical studies, Brilacidin shown to synergize with marketed antifungals against pathogenic species of aspergillosis, candidiasis, cryptococcosis and mucormycosis, and further exhibited potent stand-alone efficacy against Cryptococ…
Brilacidin shown to inhibit multiple alphaviruses, the bunyavirus Rift Valley Rift Fever, and Echovirus (a non-enveloped picornavirus) WAKEFIELD, MA / ACCESSWIRE / September 15, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"…
WAKEFIELD, MA / ACCESSWIRE / September 13, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today updated shareholders on recent progress by BT BeaMedical Technologies Ltd. ("BeaMe…
WAKEFIELD, MA / ACCESSWIRE / August 5, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's defensin-mimetic drug candidate exhibiting br…
WAKEFIELD, MA / ACCESSWIRE / July 22, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on the Company's Brilacidin program in Oral Mucositis (OM). Brilacid…
Research was performed by scientists at George Mason University's Center for Infectious Disease Research (formerly NCBID) WAKEFIELD, MA / ACCESSWIRE / June 28, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stag…
WAKEFIELD, MA / ACCESSWIRE / June 23, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported that Brilacidin, the Company's defensin-mimetic drug candidate exhibiting broa…
Innovation Pharmaceuticals acquires a minority ownership Squalus has invented and is developing a leading-edge image guided surgical laser platform for treating previously inoperable cases of epilepsy and for enabling new treatment options…
In other news, Scientific Advisor, William F. DeGrado, PhD, gives keynote lecture at 2021 Faraday Discussion and co-awarded John Scott Medal WAKEFIELD, MA / ACCESSWIRE / March 15, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Compan…
WAKEFIELD, MA / ACCESSWIRE / March 7, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported findings from data review of the Company's Brilacidin Phase 2 COVID-19 study a…
WAKEFIELD, MA / ACCESSWIRE / December 7, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provides shareholders with perspectives on the Company's go-forward strategy heading…
WAKEFIELD, MA / ACCESSWIRE / November 18, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on clinical development plans for Brilacidin, the Company's defe…
Additionally, new in vitro data also show Brilacidin targets both viral proteins and host factors, suggesting Brilacidin would be less prone to developing resistance compared to other antivirals WAKEFIELD, MA / ACCESSWIRE / November 12, 20…
WAKEFIELD, MA / ACCESSWIRE / November 11, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported topline results from the Company's Phase 2 clinical trial of Brilacidin in…
WAKEFIELD, MA / ACCESSWIRE / November 3, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical-stage biopharmaceutical company, today announced that the Company has received confirmation that hard lock of the database…